Insider Buying: RxSight, Inc. (NASDAQ:RXST) Director Buys 1,443 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley acquired 1,443 shares of RxSight stock in a transaction on Wednesday, January 15th. The stock was acquired at an average price of $31.18 per share, with a total value of $44,992.74. Following the purchase, the director now directly owns 1,443 shares in the company, valued at approximately $44,992.74. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jesse Anderson Corley also recently made the following trade(s):

• On Tuesday, November 12th, Jesse Anderson Corley acquired 11,111 shares of RxSight stock. The shares were purchased at an average cost of $45.37 per share, with a total value of $504,106.07.

RxSight Stock Down 2.5 %

NASDAQ RXST traded down $0.79 during trading hours on Friday, reaching $30.39. The company’s stock had a trading volume of 627,464 shares, compared to its average volume of 782,669. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -36.61 and a beta of 1.20. The firm’s 50-day moving average price is $39.32 and its 200-day moving average price is $46.95. RxSight, Inc. has a 1 year low of $26.29 and a 1 year high of $66.54.

Institutional Investors Weigh In On RxSight

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC grew its position in shares of RxSight by 854.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock worth $29,000 after buying an additional 521 shares in the last quarter. Quarry LP lifted its stake in RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after acquiring an additional 288 shares during the period. Point72 Hong Kong Ltd bought a new position in RxSight during the 3rd quarter worth about $34,000. Quest Partners LLC bought a new stake in shares of RxSight in the 2nd quarter valued at about $41,000. Finally, Amalgamated Bank lifted its position in shares of RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after purchasing an additional 207 shares during the period. Institutional investors own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company lowered their price objective on RxSight from $42.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday. UBS Group started coverage on shares of RxSight in a research report on Friday, December 6th. They set a “buy” rating and a $52.00 price objective on the stock. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Stifel Nicolaus cut their price objective on RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a research report on Monday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $66.00 target price on shares of RxSight in a research report on Monday. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $58.13.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.